London-based venture capital firm, 4BIO Capital, specializing in advanced therapies and emerging technologies, has made significant announcements regarding its Advisory Board and internal promotions.
These strategic moves underscore the firm’s commitment to bolstering its expertise and leadership team.
Advisory Board Appointments
The firm welcomes Abbas Hussain and Leszek Lisowski, PhD MBA, to its Advisory Board.
Abbas Hussain, a veteran in the biopharmaceutical industry with over 30 years of experience, brings a wealth of knowledge, having served as the CEO of Vifor Pharma and held pivotal roles at GSK and Eli Lilly.
Leszek Lisowski, a renowned vectorology expert, has over two decades of experience in developing and manufacturing viral vectors.
His contributions include co-founding LogicBio Therapeutics and establishing gene therapy companies in Australia.
Promotion to Principal
In a notable internal promotion, Dr. Natalie Johnston has been elevated to the position of Principal.
Dr. Johnston, who joined 4BIO Capital in September 2019, has demonstrated valuable contributions in her role as Investment Associate.
Her promotion reflects the recognition of her expertise and dedication within the organization.
The addition of Abbas Hussain and Leszek Lisowski to the Advisory Board enhances 4BIO Capital’s strategic guidance, drawing from their extensive industry experience.
These appointments signal the firm’s commitment to staying at the forefront of advancements in biopharmaceuticals and vector-based gene therapies.
Recognition and Growth
Dr. Natalie Johnston’s promotion to Principal acknowledges her significant contributions to the firm’s investment strategies.
Her elevation reflects 4BIO Capital’s emphasis on recognizing and nurturing talent from within, fostering a culture of growth and expertise development.
About 4BIO Capital
As a venture capital firm with a focus on advanced therapies, 4BIO Capital aims to invest in and support early-stage companies developing treatments in areas with high unmet medical needs.
The firm’s target areas include genomic medicines, cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.
These appointments and promotions align with the firm’s mission to unlock future treatments and ensure widespread access to transformative therapies.
Strategic Outlook
With these strategic appointments and promotions, 4BIO Capital positions itself for continued success in navigating the evolving landscape of advanced therapies and emerging technologies.
The diverse expertise brought by the Advisory Board and the internal promotion reflect the firm’s commitment to innovation and excellence in the field.
Business News
Mine Crypto. Earn $GOATS while it is free! Click Here!!